These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15963272)

  • 1. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
    Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
    Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of antibiotic resistance in respiratory tract infections.
    Klugman KP
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S6-10. PubMed ID: 17307654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV; Brown SD
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections.
    Marrie TJ
    Int J Clin Pract; 2004 Aug; 58(8):769-76. PubMed ID: 15372850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
    Low DE
    Infect Dis Clin North Am; 2013 Mar; 27(1):87-97. PubMed ID: 23398867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteremic pneumococcal pneumonia associated with macrolide failure.
    Dylewski J; Davidson R
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):39-42. PubMed ID: 16411124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
    Farrell DJ; Jenkins SG
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i17-22. PubMed ID: 15265832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
    Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of Macrolide-Induced Inhibition of Pneumolysin Release Involves Impairment of Autolysin Release in Macrolide-Resistant Streptococcus pneumoniae.
    Domon H; Maekawa T; Yonezawa D; Nagai K; Oda M; Yanagihara K; Terao Y
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181369
    [No Abstract]   [Full Text] [Related]  

  • 19. Penicillin-resistant pneumococci-implications for management of community-acquired pneumonia and meningitis.
    Ziglam HM; Finch RG
    Int J Infect Dis; 2002 Mar; 6 Suppl 1():S14-20. PubMed ID: 12044285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
    Jacobs MR
    Clin Infect Dis; 2002 Sep; 35(5):565-9. PubMed ID: 12173130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.